SCHEMBL222918

SCHEMBL222918

CCNC(=O)Nc1nc2cc(-c3cnc(N)nc3)cc(Br)c2s1

nearest known ligand 0.46

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ABL1 P00519 8/20 0.45
PIK3CG P48736 1/20 0.42
PIK3CD O00329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222045 0.89 PIK3CA (0.50) PIK3CANPC1RAB9ASMN1; SMN2ABL1
SCHEMBL2739814 0.88 PIK3CA (0.47) PIK3CANPC1RAB9ASMN1; SMN2ABL1
SCHEMBL15260270 0.86 NPC1 (0.43) PIK3CANPC1RAB9ASMN1; SMN2ABL1
SCHEMBL221710 0.84 NPC1 (0.45) PIK3CANPC1RAB9ASMN1; SMN2ABL1
SCHEMBL220751 0.83 ABL1 (0.47) PIK3CANPC1RAB9ASMN1; SMN2ABL1
SCHEMBL16975481 0.82 ABL1 (0.40) PIK3CANPC1RAB9ASMN1; SMN2ABL1
SCHEMBL2739677 0.82 MAPK1 (0.49) PIK3CANPC1RAB9ASMN1; SMN2ABL1
SCHEMBL2739670 0.82 PIK3CG (0.50) PIK3CANPC1RAB9ASMN1; SMN2ABL1
SCHEMBL2739684 0.81
SCHEMBL2739811 0.81 ABL1 (0.44) PIK3CANPC1RAB9ASMN1; SMN2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481544-B2 Antibacterial compositions BIOTA EUROPE LIMITED (GB) 2013-07-09 US disclosed
US-8389516-B2 Antibacterial compositions BIOTA EUROPE LIMITED (GB) 2013-03-05 US disclosed
EP-2034997-B1 ANTIBACTERIAL COMPOSITIONS BIOTA EUROPE LTD (GB) 2012-10-17 EP disclosed
US-20120004221-A1 Antibacterial Compositions BIOTA EUROPE LIMITED (GB) 2012-01-05 US disclosed
US-20110263590-A1 Antibacterial Compositions BIOTA EUROPE LIMITED (GB) 2011-10-27 US disclosed
US-7977340-B2 Antibacterial compositions PROLYSIS LTD. (GB) 2011-07-12 US disclosed
US-20090197877-A1 Antibacterial Compositions PROLYSIS LTD. (GB) 2009-08-06 US disclosed
CN-101472585-A Antibacterial compositions PROLYSIS LTD (GB) 2009-07-01 CN disclosed
EP-2034997-A1 ANTIBACTERIAL COMPOSITIONS Prolysis Limited (GB) 2009-03-18 EP disclosed
WO-2007148093-A1 ANTIBACTERIAL COMPOSITIONS PROLYSIS LTD. (GB) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004221-A1 Antibacterial Compositions CYCS, COX6C, RPS6 PIK3CA 4048/4885NPC1 2581/4885RAB9A 3590/4885
US-20090197877-A1 Antibacterial Compositions CYCS, COX6C, INTS6 PIK3CA 3650/4885NPC1 3471/4885RAB9A 3588/4885
US-20110263590-A1 Antibacterial Compositions CYCS, COX6C, RPS6 PIK3CA 4048/4885NPC1 2378/4885RAB9A 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.